Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Stock Traders Daily
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Issues FY 2013 Guidance; EPS Guidance Above Analysts' Estimates; Reaffirms FY 2012 Guidance; Reaffirms FY 2014 Guidance

Friday, 4 Jan 2013 07:30am EST 

Eli Lilly And Co announced that it has confirmed previously published fiscal 2012 earnings per share (EPS) guidance in the range of $3.68-$3.78 on a reported basis, or $3.30 to $3.40 on a non-GAAP basis when excluding $.43 per share of income from the early payment of Amylin's exenatide revenue sharing obligation and $.05 per share of asset impairment and restructuring charges through the first nine months of 2012. For fiscal 2013, it expects earnings per share (EPS) to be in the range of $4.03 to $4.18 on a reported basis, or $3.75 to $3.90 on a non-GAAP basis when excluding an estimated $.28 per share of exenatide-related income contingent upon the transfer of exenatide commercial rights outside the U.S. to Amylin and revenue between $22.6 billion and $23.4 billion. The Company remains on track to meet or exceed minimum financial performance targets. From now through fiscal 2014, on an annual basis the Company still expect revenue to be at least $20 billion, net income to be at least $3 billion. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $3.71 and revenues of $22.8 billion for fiscal 2013; revenue of $22 billion and net income of $3.7 billion for fiscal 2014. 

Company Quote

0.31 +0.50%
11 Jul 2014